Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 7/20 | 0.34 |
| ▸ | LIPE | Q05469 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580259 | 0.88 | FADS1 (0.40) | FADS1TP53LIPEPIK3CDPIK3CB | |
| SCHEMBL2998780 | 0.87 | FADS1 (0.43) | FADS1TP53LIPEPIK3CDPIK3CB | |
| SCHEMBL2563076 | 0.85 | FADS1 (0.42) | FADS1TP53LIPEPIK3CDPIK3CB | |
| SCHEMBL2566533 | 0.84 | FADS1 (0.44) | FADS1TP53LIPEPIK3CDPIK3CB | |
| SCHEMBL2566536 | 0.83 | FADS1 (0.43) | FADS1TP53LIPEPIK3CDPIK3CB | |
| SCHEMBL2567315 | 0.79 | FADS1 (0.44) | FADS1TP53PIK3CDPIK3CBPIK3CG | |
| SCHEMBL3004175 | 0.78 | FADS1 (0.44) | FADS1TP53KMT2AMEN1LMNA | |
| SCHEMBL2567416 | 0.78 | FADS1 (0.47) | FADS1TP53PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2559985 | 0.77 | FADS1 (0.51) | FADS1TP53PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2561473 | 0.77 | FADS1 (0.49) | FADS1TP53PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | FADS1 140/4885TP53 836/4885LIPE 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.